Oncolytics Biotech (ONCY) said Tuesday it has received a US patent covering pelareorep manufacturing process into 2044.
The firm also said it plans to file additional patent applications this year to expand intellectual property protection for pelareorep across additional therapeutic uses and treatment settings.
Oncolytics is developing pelareorep, an investigational intravenously delivered ribonucleic acid immunotherapeutic agent.
Shares were 5% higher in morning trading.
Price: 0.89, Change: +0.04, Percent Change: +5.08
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments